Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. TScan Therapeutics Inc.’s current trading price is -52.07% away from its 52-week high, while its distance from the 52-week low is 99.31%. The stock’s price range over this period has fluctuated between $1.45 and $6.03. The company, operating within the financial sector, had a trading volume of approximately 1.35 million for the day, which was noticeably higher than the average daily share volume of 0.12 million over the last 3 months.
The stock of TScan Therapeutics Inc. (TCRX) is currently priced at $2.89. In the last session, the stock climbed significantly, topping out at $2.93 after opening at $2.39. The day’s lowest price was $2.36 before the stock closed at $2.45.
TScan Therapeutics Inc. experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $6.03 on 05/09/23, while the lowest price for the same period was registered at $1.45 on 12/27/22.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
TScan Therapeutics Inc. (TCRX) has experienced a quarterly rise of 6.25% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 117.19M and boasts a workforce of 135 employees.
TScan Therapeutics Inc.: What Analysts Are Saying
As of right now, 3 analysts are rating TScan Therapeutics Inc. as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.53, with a change in price of +0.42. Similarly, TScan Therapeutics Inc. recorded 1,013,105 in trading volume during the last 100 days, posting a change of +17.00%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for TCRX stands at 0.16. Similarly, the long-term debt-to-equity ratio is also 0.16.
TCRX Stock Stochastic Average
Today, TScan Therapeutics Inc.’s raw stochastic average for the past 50 days stands at 96.00%, indicating a rise from the raw stochastic average of the last 20 days, which was 95.83%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 81.52% and 80.88% respectively.
TCRX Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant gain of 86.45% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 10.31%. Over the past 30 days, the price of TCRX has fallen by 37.62%. And in the last five days, it has surged by 19.92%.